Autolus Therapeutics Reports 95% Q3 Revenue Growth and Raises Full-Year Guidance
Autolus Therapeutics (AUTL) reported strong third-quarter financial results for 2026, highlighted by a 95% year-over-year increase in net product revenue to $41.2 million. The company raised its full-year revenue guidance to at least $150 million, up from the previous range of $140 million to $150 million. This growth is supported by significant manufacturing efficiencies at the Nucleus facility, which allowed the company to double production volume compared to 2025 while maintaining lower staffing levels. Financial stability remains a key theme as Autolus reported a narrowing net loss of $55.1 million, down from $79.1 million in the prior-year period. The company holds $248.4 million in cash and marketable securities, providing a projected operational runway into the second quarter of 2028. While clinical data timelines for certain studies like the Progressive MS trial have been pushed to October 2027, the company continues to expand its footprint with 90 authorized treatment centers in the U.S.
Topics: Financial Guidance Gross Margin Improvement Manufacturing Efficiency Revenue Growth
Read the full article at Motley Fool
Part of the story Vodafone Reports Accelerated Revenue Growth and Upgrades Full-Year Guidance (14 articles)